drugset
drugset / Trial / NCT01303536

Ondansetron Augmentation in Treatment-resistant OCD

NCT01303536 ↗

Phase 4 Completed 21 enrolled Institute of Neuroscience, Florence, Italy
NaSingle-groupSingle-blindTreatment

Summary

The aim of this study is to evaluate whether ondansetron augmentation to SSRI will improve and ondansetron discontinuation will result in worsening of obsessive compulsive symptoms among obsessive compulsive disorder resistant patients.

Timeline

Start
2009-12
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 0.5 mg Oral

Indications

obsessive-compulsive disorder